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ABSTRACT: 
OBJECTIVE: Raised plasma endothelin-1 (ET-1) levels may be a risk factor for vascular 
dysfunction and cardiovascular (CV) disease. This meta-analysis assessed the effect of statins on 
circulating ET-1 concentrations 
METHODS AND RESULTS: The search included PUBMED, Cochrane Library, Web of 
Science, Scopus, and EMBASE up to September 30, 2014 to identify randomized controlled 
trials (RCTs) with ET-1 measurement during statin therapy. Quantitative data synthesis was 
performed using a random-effects model, with weighed mean difference (WMD) and 95% 
confidence interval (CI) as summary statistics. Data from 15 RCTs showed that statin therapy 
significantly reduces plasma ET-1 concentrations (WMD: -0.30 pg/mL, 95%CI: -0.47, -0.13; 
p<0.01). This effect was robust in sensitivity analysis, and not largely affected by the duration of 
statin therapy (<12 weeks – WMD: -0.51 pg/mL, 95%CI: -0.89, -0.14, p<0.01; >12 week –
WMD: -0.19 pg/mL, 95%CI: -0.36, -0.02; p<0.05) or by dose of statins (<40 mg/day – WMD: -
0.27 pg/mL, 95%CI: -0.49, -0.05; p=0.01; >40 mg/day – WMD: -0.38 pg/mL, 95%CI: -0.68, -
0.08; p=0.01). Lipophilic (atorvastatin, simvastatin, fluvastatin, and cerivastatin – WMD: -0.34 
pg/mL, 95%CI: -0.55, -0.13; p<0.01), but not a hydrophilic statin (pravastatin – WMD: -0.18 
pg/mL, 95%CI: -0.44 -0.08; p>0.05) had a significant effect in promoting ET-1 reduction.  
CONCLUSIONS: Statin therapy significantly reduces circulating ET-1 concentrations, 
regardless of treatment duration or dose of statins. This effect of statins may be influenced by 
statin lipophilicity. There is a need to establish whether lowering ET-1 levels has a beneficial 
effect on CV events. 
 
Keywords: endothelin-1, endothelial dysfunction, lipophilicity, statins, therapy. 
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BACKGROUND 
Atherosclerosis leads to cardiovascular diseases (CVD), a major cause of morbidity and 
mortality 1, 2. The endothelium plays a role in atherogenesis, and endothelial dysfunction is 
considered to be involved in the onset of CVD and its progression 2. Endothelial dysfunction  
results in reduced nitric oxide and prostacyclin bioavailability, vasoconstriction, oxidative stress, 
inflammation, and platelet activation  3, 4. 
Among molecules that may modulate endothelial function, endothelin-1 (ET-1) is a peptide, 
which is primarily produced by vascular endothelial cells 5. ET-1 was first identified as a 
vasoconstrictor 6. The synthesis of ET-1 starts from precursor peptides; endothelin-converting 
enzyme converts pro-endothelin to ET-1 7. ET-1 is multifunctional, and  promotes  inflammation 
and cell proliferation within arterial vessel walls 5. The synthesis of ET-1 is mediated by various 
factors, including  oxidized low-density lipoprotein (LDL), platelet activation, and hypoxia 8-10. 
Conversely, ET-1 may also induce LDL oxidation and platelet activation 11. Thus, over-
production of ET-1 may be associated with increased risk for CVD 5. The control of ET-1 
expression might provide benefits against the development of atherosclerosis and CVD  events.  
Consistent with this is the observation that antagonism of the ET-1 system can modify 
atherogenesis 12.  
Many clinical trials have reported the beneficial effects of statins in CVD prevention 13-16. 
Recently, attention has been paid to the pleiotropic actions of statins beyond simple cholesterol-
lowering 17-19. In experimental studies, statins can inhibit ET-1 production 20; however, findings 
concerning changes in ET-1 concentrations following statin therapy have been inconsistent. 
Therefore, in the present meta-analysis we evaluated the impact of statin therapy on circulating 
ET-1 concentrations. 
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METHODS  
Search Strategy 
This study was designed according to the guidelines of the 2009 preferred reporting items 
for systematic reviews and meta-analysis (PRISMA) statement 21. Our search included SCOPUS 
(http://www.scopus.com), Medline (http://www.ncbi.nlm.nih.gov/pubmed), Web of Science 
(http://apps.webofknowledge.com), and Cochrane Library (www.thecochranelibrary.com/) 
databases. It was limited to randomized controlled trials (RCTs) carried out from January 1, 1970 
to September 30, 2014, investigating the potential effects of statin therapy on ET-1 
concentrations. The databases were searched using the following search terms in titles and 
abstracts (also in combination with MESH terms): (rosuvastatin or pravastatin or fluvastatin or 
simvastatin or atorvastatin or pitavastatin or lovastatin or cerivastatin or “statin therapy” or 
statins) and (endothelin-1 or endothelin or ET-1). The wild-card term ‘‘*’’ was used to increase 
the sensitivity of the search strategy. No language restriction was used in the literature search. 
The search was limited to studies in human. Two reviewers (CS and AS) evaluated each article 
separately. Disagreements were resolved by discussion with a third party (MB).  
 
Study Selection 
Original studies were included if they met the following inclusion criteria: (i) a randomized 
controlled trial (RCT) in either parallel or cross-over design, (ii) investigating the impact of 
statin therapy on plasma/serum levels of ET-1, (iii) treatment duration of at least two weeks, and, 
(iv) presentation of sufficient information on ET-1 concentrations at baseline and at the end of 
study in both statin and control groups or providing the net changes in each group.  
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Exclusion criteria were: (i) non-clinical studies, (ii) uncontrolled trials, (iii) lack of sufficient 
information on baseline or follow-up ET-1 levels, (iv) inability to obtain adequate details of 
study methodology or results from the article or the investigators, and, (v) the study was 
ongoing. Exclusion of an article for the latter reason was carried out if no feedback was received 
after contacting the author(s). 
 
Data extraction  
Eligible studies were reviewed and the following data were abstracted: 1) first author's 
name, 2) year of publication, 3) study location, 4) number of participants in the statin and control 
groups, 5) age, gender and body mass index (BMI) of study participants, 6) baseline levels of 
total cholesterol, LDL cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), 
triglycerides, high-sensitivity C-reactive protein (hsCRP) and glucose, 7) systolic and diastolic 
blood pressure, and, 8) data regarding baseline and follow-up concentrations of ET-1. In case the 
values were only presented as graphs, the GetData Graph Digitizer 2.24 (http://getdata-graph-
digitizer.com/) software was used to digitize and extract the data. 
 
Quality assessment 
The quality of included studies was assessed using the Jadad scale. This scale encompasses 
randomization (0-2 points), blinding (0-2 points), and dropouts and withdrawals (0-1 point). The 
overall score of a study according to this scale ranges between 0-5, with higher scores indicative 
of a better quality 22. Studies with Jadad scores of ≤2 and ≥3 were considered as low- and high-
quality, respectively 23. 
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Quantitative Data Synthesis 
Meta-analysis was conducted using Review Manager, version 5.2 (Cochrane Collaboration), 
and Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ) 24. Standard deviations 
(SDs) of the mean difference were calculated using the following formula: SD = square root 
[(SDpre-treatment)2 + (SDpost-treatment)2 – (2R × SDpre-treatment × SDpost-treatment)], assuming a correlation 
coefficient (R) = 0.5. In case of reporting SEM, SD was estimated using the following formula: 
SD = SEM × sqrt (n), where n is the number of subjects. 
Net changes in measurements (change scores) were calculated for parallel and cross-over 
trials, as follows: (measure at end of follow-up in the treatment group − measure at baseline in 
the treatment group) − (measure at end of follow-up in the control group − measure at baseline in 
the control group). A random-effects model (using DerSimonian-Laird method) and the generic 
inverse variance method were used to compensate for the heterogeneity of studies in terms of 
statin type, statin dose, study design, treatment duration, and the characteristics of populations 
being studied 25. Effect sizes were expressed as weighed mean difference (WMD) and 95% 
confidence interval (CI). Post-hoc subgroup analyses were carried out to explore the impact of 
dose (<40 mg/day vs >40 mg/day), duration (<12 weeks vs >12 weeks), and type (lipophilic vs 
hydrophilic) of statin therapy on plasma ET-1 concentrations. In order to evaluate the influence 
of each study on the overall effect size, sensitivity analysis was conducted using the one-study 
remove (leave-one-out) approach 26. The power of analysis to detect statistically significant 
difference between statin and control groups was performed using the PS software 27. 
In the absence of trials making head-to-head comparison of hydrophilic versus lipophilic 
statins, the effect of these two types of statins on plasma ET-1 levels were compared using 
adjusted indirect comparison according to the method proposed by Song et al. 28 and Bucher et 
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al. 29. In this method, treatment effects estimated for each type of statins in the random-effects 
model could be compared indirectly through common controls. 
 
Meta-regression 
Random-effects meta-regression was performed using unrestricted maximum likelihood 
method to evaluate the association between calculated WMD in plasma ET-1 concentrations with 
duration and dose of treatment with statins, as well as age, gender and changes in plasma 
LDL-C concentrations as potential moderators of treatment response. 
 
Publication bias 
Potential publication bias was explored using visual inspection of Begg’s funnel plot 
asymmetry, and Begg’s rank correlation and Egger’s weighted regression tests. Duval and 
Tweedie “trim and fill” and “fail-safe N” methods were used to adjust the analysis for the effects 
of publication bias 30. 
 
Heterogeneity Analysis 
Heterogeneity analysis was performed using the Cochrane’s Q test and I2 index. Another 
attempt to explore heterogeneity was made via the Galbraith plot, a scatter plot of WMD divided 
by its standard error (Z-statistic) against the reciprocal of the standard error in the included 
studies. 
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RESULTS 
The initial screening for potential relevance removed the articles in whose titles and/or 
abstracts were obviously irrelevant. Among the 30 full text articles assessed for eligibility, 15 
studies were excluded because of: lack of assessment of plasma ET-1 concentrations (n=1), 
insufficient data on plasma ET-1 levels (n=4), not being an original research study (n=1), not 
having an appropriate RCT design (n=4), short (<2 weeks) duration of treatment (n=2) and non-
English language (n=3) (Figure 1).  
 
Characteristics of included studies 
After final assessment, 15 RCTs 31-45 met the inclusion criteria and were considered for the 
final meta-analysis. In total, 810 participants were randomized, of whom 421 were allocated to 
statin intervention and 389 to controls. The number of participants in these trials ranged from 32 
to 82. Included studies were published between 1999 and 2013, and were conducted in Egypt, 
Norway, Russian Federation, Canada, USA (2 trials), Italy, Taiwan (3 trials), Poland, China, 
Japan, Sweden, and India. The following statin doses were administered in the included trials: 10 
to 80 mg atorvastatin/day, 10 to 40 mg pravastatin/day, 40 mg/day simvastatin and fluvastatin, 
and 0.15 mg/day cerivastatin. Duration of statin intervention ranged between 2 weeks and 12 
months. 12 trials were designed as parallel-group studies and 3 as crossover, comprising a total 
of 16 treatment arms. The measurements of ET-1 concentrations were based on the 
immunoassays in all the included studies. Demographic and baseline parameters of the 
included studies are shown in Table 1. The systematic assessment of bias in the included studies 
is shown in Supplemental Table 1.  
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Quantitative data synthesis 
The meta-analysis of data from 15 RCTs (comprising 16 treatment arms) 31-45 showed a 
significant effect of statin therapy in reducing plasma ET-1 concentrations (WMD: -0.30 pg/mL, 
95%CI: -0.47, -0.13; p = 0.0004; power = 100%) (Figure 2). This effect size was robust in 
sensitivity analysis and omission of a single study did not significantly change the overall 
estimated effect size (Supplemental Figure 1). When the analysis was repeated using the 
fixed-effects model, significant results were again obtained (WMD: -0.16 pg/mL, 95%CI: -
0.23, -0.09; p < 0.00001). In the subgroup analysis, the effect of statins on plasma ET-1 was 
significant in both subsets of studies with treatment durations >12 weeks (WMD: -0.19 pg/mL, 
95%CI: -0.36, -0.02; p = 0.03) and <12 weeks (WMD: -0.51 pg/mL, 95%CI: -0.89, -0.14,            
p = 0.008) (Figure 3). With respect to statin dose, a significant reduction of plasma ET-1 levels 
was observed with both statin doses <40 mg/day (WMD: -0.27 pg/mL, 95%CI: -0.49, -0.05;         
p = 0.01) and >40 mg/day (WMD: -0.38 pg/mL, 95%CI: -0.68, -0.08, p = 0.01) (Figure 4). 
 
Adjusted indirect meta-analysis 
In order to compare the effects of hydrophilic versus lipophilic statins on plasma ET-1 
levels, a subgroup analysis was first conducted to estimate the effect size. In the subgroup 
analysis, lipophilic (comprising 7 treatment arms with atorvastatin, 2 arms with simvastatin, 1 
arm with fluvastatin and 1 arm with cerivastatin) (WMD: -0.34 pg/mL, 95%CI: -0.55, -0.13;           
p = 0.001) but not hydrophilic (comprising 5 treatment arms with pravastatin) (WMD: -0.18 
pg/mL, 95%CI: -0.44, 0.08, p = 0.17) statins had a significant effect in lowering plasma ET-1 
levels (Figure 5). A superior effect of lipophilic compared with hydrophilic statins was also 
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confirmed in the adjusted indirect comparison, where the effect size was estimated to be -0.16 
pg/mL (95%CI: -0.20, -0.12, Z = 7.62, p < 0.05; power = 100%). 
 
Meta-regression 
The meta-regression analysis was conducted to assess the association of changes in plasma 
ET-1 concentrations with dose and duration of statin therapy as potential moderator variables. 
Consistent with the results of subgroup analysis, the impact of statins on plasma ET-1 
concentrations was found to be independent of administered dose (slope: 0.001; 95%CI: -0.008 
to 0.010; p = 0.808) and duration of supplementation (slope: -0.002; 95%CI: -0.030 to 0.026;         
p = 0.888). In addition, no significant association was found between changes in plasma 
LDL-C concentrations (slope: 0.004; 95%CI: -0.007 to 0.016; p = 0.439), baseline age 
(slope: -0.010; 95%CI: -0.039 to 0.019; p = 0.502), and sex (frequency of male subjects in 
each study) (slope: 0.005; 95%CI: -0.007 to 0.017; p = 0.449) with the changes in plasma 
ET-1 concentrations (Supplemental Figure 2). 
 
Publication bias 
The funnel plot of the study precision (inverse standard error) by effect size (mean 
difference) was asymmetric and suggested potential publication bias. This observation was 
further supported by the results of Begg’s rank correlation (Kendall’s Tau with continuity 
correction = -0.39, Z = 2.12, two-tailed p-value = 0.034) and Egger’s linear regression (intercept 
= -2.49, standard error = 0.83; 95%CI = -4.26, -0.71, t = 3.01, df = 14.00, two-tailed p = 0.009) 
tests. The observed publication bias was imputed using trim-and-fill correction. Two potentially 
missing studies were imputed leading to a corrected effect size that was still significant -0.25 
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pg/mL (95%CI: -0.42, -0.09). The “fail safe N” method indicated that 156 theoretically missing 
studies would be required to make the overall estimated effect size non-significant. Funnel plot 
of the impact of statins on plasma ET-1 concentrations is illustrated in Supplemental Figure 3.  
 
Heterogeneity analysis 
The meta-analysis indicated a significant heterogeneity based on the calculated I2 value of 
75%, thus supporting the choice of random-effects model. A Galbraith plot was used to identify 
RCTs that are outside the pooled 95%CI estimate and might serve as potential outliers causing 
heterogeneity. According to the plot, 4 RCTs 39-41, 46 resided outside the limits of the 95%CI. A 
second analysis excluding these 4 RCTs showed a low inter-study heterogeneity (I2 = 10%); yet 
the pooled effect turned out to be marginally significant (WMD: -0.08 pg/mL, 95%CI: -0.16- 
0.00; p = 0.06) (Supplemental Figure 4). This latter analysis yielded significant results 
under the fixed-effects model (WMD: -0.08 pg/mL, 95%CI: -0.15-0.00; p = 0.05). 
 
DISCUSSION 
The present meta-analysis suggests that statin therapy reduces plasma ET-1 concentrations. 
The efficacy of statins was independent of therapeutic duration or dose. Since there have been 
no intervention studies specific for the reduction of ET-1 levels in relation to the CVD 
outcomes, the relevance of the mean level of the reduction (-0.30 pg/mL) on CVD 
prevention still remains to be determined. Even if so, these findings are of large interest 
since ET-1 may be a potential therapeutic target for atheroprotection 5. 
The robustness of our combined analysis was verified in sensitivity analysis and it was 
found that the significance of the pooled estimate is the result of all studies rather than a single 
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study. Our analysis included a study with cerivastatin that is a statin withdrawn from the market. 
However, when the analysis was repeated after excluding the cerivastatin arm, the result 
remained significant (WMD: -0.26 pg/mL, 95%CI: -0.41, -0.10; p = 0.002). In this analysis, 
although a greater effect size was calculated for the subset of trials with <12 weeks 
treatment duration compared with the subset lasting >12 weeks, no association between 
treatment duration and effect size was found in the meta-regression analysis. It may be 
hypothesized that the greater effect in the subset of trials with <12 weeks duration might be 
due to the fact that all studies – except one 34 - in this subset used lipophilic statins, which 
were found to have a greater effect compared with hydrophilic statins in terms of reducing 
plasma ET-1 levels. In contrast, there were four trials 35-38 with hydrophilic statins in the 
subset of trials with >12 weeks treatment duration.  
The biological mechanisms involved in the reduction of ET-1 by statins are not completely 
known. Some experimental studies report that statins may inhibit ET-1 expression at the 
transcriptional level in vascular endothelial cells 20. In addition, ET-1 is synthesized by 
conditions in which oxidized LDL, platelet activation and oxidative stress exist 9, 10, 47. Statins 
inhibit these conditions 17, 18, 48, 49. More studies are required. 
ET-1 in the circulation mainly stems from vascular cells 5, while urinary ET-1 is thought to 
reflect kidney derived production 50.  It has been suggested that urinary ET-1 reflects overall 
endogenous production of this protein 51. Besides plasma ET-1 measurement, 4 studies included 
in this meta-analysis measured urinary ET-1 levels; they confirmed a significant reduction of 
urinary ET-1 during statin therapy 36-38, 41. 
In addition to cholesterol-lowering effects, the so-called pleiotropic effects of statins have 
been the subject of increasing debate 17, 18. These effects may be mainly due to LDL-C reduction 
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(and in turn, plaque stabilization, reduced inflammation, and oxidative stress, etc.)52. Variations 
in these pleiotropic effects might decrease residual CVD risk. While there is a correlation 
between ET-1 and LDL oxidation 8, 11, ET-1 concentrations are not clearly correlated with 
LDL-C levels. Future clinical studies are needed to determine to what degree the reduction 
of ET-1 is independent of an anti-oxidative pleiotropic effect of statins. 
We show a possible superior effect of lipophilic compared with hydrophilic statins on the 
reduction of ET-1. There is also additional evidence (besides data on pravastatin), which shows 
no significant effect of rosuvastatin on plasma ET-1 concentrations 52, 53. A debate exists about 
the clinical impact of statin lipophilicity 54-59, as disposition of hydrophilic statins could be 
mediated via active transporters 60. The reasons for the different effects of lipophilic/hydrophilic 
statins on ET-1 may be due to a wider tissue distribution with lipophilic statins 61. Unlike the 
hepatic tissue, uptake of hydrophilic statins by non-hepatic tissues such as vascular cells and 
myocardial tissue, as the sources of ET-1, is less than lipophilic statins 62, 63. A recent meta-
analysis of 13 RCTs indicated that lipophilic statins are better than hydrophilic statins for the 
treatment of heart failure 64. The issue of statin lipophilicity requires further investigation; in our 
opinion, until that time lipophilicity should not influence the choice of statin.    
This meta-analysis has limitations. The studies included had relatively short follow-up 
durations (2 weeks – 12 months) and most had a small number of participants (32 - 82). 
Furthermore, in relation to the study durations, they did not assess long-term CVD outcomes. 
The variations in study durations and statin doses may have not been of sufficient diversity 
to assess the impact of these factors on the ET-1-lowering effect of statins. Therefore, there 
is still a need for data from additional trials to identify determinants of ET-1 response to 
statin therapy, and also the impact of novel LDL-lowering agents 65, 66 on plasma ET-1 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
14 
 
levels. To address inter-study heterogeneity, a conservative random-effects model was 
applied. In addition, sensitivity analysis confirmed that the pooled estimate is not significantly 
deviated by a single study. 
 
CONCLUSIONS 
In conclusion, the findings of the present meta-analysis suggest that statin therapy 
significantly reduces plasma ET-1 concentrations, regardless of treatment duration or statin dose. 
Statin properties, such as lipophilicity, may affect the level of ET-1 reduction. Larger, well-
designed studies with longer follow-up are needed to validate our findings, and to 
determine the parameters that could determine ET-1 response to statin therapy. Whether 
reduction of plasma ET-1 concentrations can prevent atherosclerosis and CV events also 
requires further investigations.  
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Table 1. Demographic characteristics of the included studies. 
Study 
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al.31 
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et al.32 
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et al.33 
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al.36 
Lee et 
al.38 
Lee et 
al.37 
Lewandow
ski et al.39 
Li & Hui 
et al.40 
Mozaffaria
n et al.42 
Nakamura 
et al.41 
Tehrani et 
al43 
Usharani et 
al.44 
Year  2007 2003 2013 1999 2004 1999 2002 2005 2009 2010 2005 2005 2001 2013 2008 
Jadad 
score 
 3 4 3 3 4 4 5 5 5 3 3 5 4 3 3 
Locatio
n 
 Egypt Norway Russian 
Federati
on 
Canada USA Italy Taiwan Taiwan Taiwan Poland China USA Japan Sweden India 
Design  Random
ized, 
placebo-
controll
ed 
parallel 
group 
trial 
Random
ized 
double-
blind 
placebo-
controlle
d 
parallel 
group 
trial 
Random
ized 
placebo-
controlle
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parallel 
group 
trial 
Randomiz
ed 
double-
blind 
placebo-
controlled 
parallel 
group trial 
Randomized 
double-blind 
placebo-
controlled parallel 
group trial 
Randomiz
ed double-
blind 
placebo-
controlled 
crossover 
group trial 
Randomi
zed 
double-
blind 
placebo-
controlle
d 
parallel-
group 
trial 
Randomi
zed 
double-
blind 
placebo-
controlle
d 
parallel-
group 
trial 
Randomi
zed 
double-
blind 
placebo-
controlle
d 
parallel-
group 
trial 
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d double-
blind 
placebo-
controlled 
parallel-
group trial 
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d double-
blind 
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controlled 
parallel-
group trial 
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blind 
placebo-
controlled 
crossover 
group trial 
Randomize
d double-
blind 
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controlled 
parallel-
group trial 
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d double-
blind 
placebo-
controlled 
crossover 
group trial 
Randomized 
placebo-
controlled 
parallel-
group trial 
Duratio
n of trial 
 6 
months 
12 
weeks 
30 days 6 weeks 12 weeks 32 weeks 6 months 12 
months 
6 months 8 weeks 2 weeks 16 weeks 6 months 2 months 8 weeks 
Inclusio
n 
criteria 
 Patients 
fulfillin
g the 
ACR 
prelimin
ary 
classific
ation 
criteria 
for 
Systemi
c 
Sclerosi
s 
Kidney 
transpla
nt 
recipient
s over 
18 yr of 
age with 
a total 
cholester
ol of 
4.0–9.0 
mmol/L 
Patients 
with 
terminal 
chronic 
renal 
failure, 
included 
in 
hemodia
lysis 
program 
not less 
than 6 
months, 
with 
dyslipid
emia, 
aged 
35–70 
yrs, 
hemoglo
bin level 
≥100 
g/L, 
urea 
reductio
n rate 
(URR) 
≥65%, 
Patients 
admitted 
to the 
coronary 
care unit 
of the 
Montreal 
Heart 
Institute 
with a 
diagnosis 
of acute 
myocardia
l 
infarction 
or 
unstable 
angina if 
they had 
admission 
total 
serum 
cholestero
l ≥5.2 
mmol/L 
or LDL 
cholestero
l ≥3.4 
mmol/L 
Patients aged 21-
80 years and at 
risk for type 2 
diabetes (either 
having a first-
degree relative 
with type 2 
diabetes and 
normal glucose 
tolerance or 
impaired glucose 
tolerance defined 
as a 2-h blood 
glucose value 
between 140–199 
mg/dl during a 
75-g oral glucose 
tolerance test) or 
had type 1 or type 
2 diabetes 
Patients 
aged 40 to 
70 years 
who had 
diastolic 
hypertensi
on and 
primary 
hyperchol
esterolemi
a and who 
were not 
taking any 
lipid-
lowering 
or 
antihypert
ensive 
drugs 
Patients 
with 
proteinuri
a and 
stable, 
well-
controlle
d 
hypertens
ion with 
a seated 
diastolic 
blood 
pressure 
of 90 mm 
Hg and 
systolic 
blood 
pressure 
of 140 
mm Hg 
at a 3-
month 
screening 
period 
Consecut
ive 
proteinuri
c patients 
with 
stable, 
well-
controlle
d 
hypertens
ion with 
a seated 
diastolic 
blood 
pressure 
of 90 mm 
Hg and 
systolic 
blood 
pressure 
of 140 
mm Hg 
at a 3-
month 
screening 
period 
Patients 
with 
chronic 
obstructi
ve 
pulmonar
y disease 
in whom 
a routine 
echocardi
ogram 
showed 
pulmonar
y 
hypertens
ion, 
stable for 
at least 3 
months 
and 
between 
40 and 80 
yrs of age 
Men with 
hypercholes
terolemia 
(total and 
LDL 
cholesterol 
levels ≥90 
and 
≥115mg/dl, 
respectively
), and mild-
to moderate 
essential 
hypertensio
n (blood 
pressures: 
140–
179/90–
109mmHg)
. 
Patients 
with 
angiographi
cally-
documente
d coronary 
artery 
disease 
Patients 
with heart 
failure and 
at least 
New York 
Heart 
Association 
class II 
symptoms 
and left 
ventricular 
ejection 
fraction 
<40% 
Normotensi
ve type 2 
diabetic 
patients 
with 
microalbum
inuria (20–
200µg/min) 
and 
dyslipidemi
a (total 
cholesterol 
>200 
mg/dl, LDL 
cholesterol 
>160 
mg/dl, 
HDL 
cholesterol 
<35 mg/dl, 
and 
triglyceride 
>150 
mg/dl) 
Patients 
aged 
between30 
and 70 yrs 
with type 1 
diabetes 
and 
elevated 
levels of 
low-density 
lipoprotein 
(LDL) 
(>2.5 
mmol/L) 
and/or total 
cholesterol 
(>4.5 
mmol/L) 
Patients with 
type 2 
diabetes, 
21–80 yrs, 
with fasting 
plasma 
glucose of 
≥130 
mg/dL, a 
glycosylated 
haemoglobi
n (HbA1c) 
range of 
between 7% 
and 11%, 
and taking 
stable 
antihypergly
caemic 
medications 
for a 2-
month 
period 
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dialysis 
dose 
≥1.2 
and serum 
triglycerid
e≥4.5 
mmol/L 
Statin 
form 
 atorvast
atin 
fluvastat
in 
atorvast
atin 
pravastati
n 
atorvastatin pravastati
n 
pravastati
n 
pravastati
n 
pravastati
n 
simvastatin simvastatin atorvastatin cerivastatin atorvastatin atorvastatin 
Statin 
interven
tion 
 40 
mg/day 
40mg/da
y 
20 
mg/day 
40 
mg/day 
20 mg/day 20 to 40 
mg/day** 
10 
mg/day 
10 
mg/day 
40 
mg/day 
40 mg/day 40 mg/day 10 mg/day 0.15 
mg/day 
80 mg/day 10 mg/day 
Particip
ants 
Case 20 37 28 28 15# 19## 25 31 42 27 15 16 22 30 20 23§ 
23§§ 
Cont
rol 
20 35 26 27 15# 18## 25 32 40 26 16 16 22 30 20 21 
Age 
(years) 
Case 59.9±10
.1 
52±13 NS 55±2.1 48±13# 51± 
14## 
53±2 50±9 50±9 71±8 39.0±10.2 NS 51±11 58±10 44 (39–61) 50.47± 
10.35§ 
55.52± 
10.76§§ 
Cont
rol 
58.7±9.
2 
51±17 NS 56±2.3 49±11# 55± 
11## 
47±8 48±8 72±6 38.3±10.1 NS 55±9 49.75±8.18 
Male 
(%) 
Case 22.5 81.1 70.59 81.48.0 54.05# 57.5## 43.0 58.06 69.05 74.07 100.0 NS 86.36 60.0 50.0 52.17§ 
52.17§§ 
Cont
rol 
12.5 71.4 76.47 92.85 65.62 67.5 73.08 100.0 NS 66.6 52.38 
BMI 
(kg/m2) 
Case NS NS NS NS 29.5±5
.8# 
29.8± 
9.4## 
25.8±4.2 24.7±1.1 24.8±1.4 22±2 28.7±4.5 NS 31.8±6.4 NS 25±3 25.03±1.83§ 
24.66±2.42§§ 
Cont
rol 
NS NS NS NS 24.5±1.2 24.6±1.3 23±1 27.3±4.1 NS NS 23.98±2.35 
hs-CRP 
(mg/L) 
Case 3.79 
(1.8) 
NS NS NS 0.24 
(0.07–
0.35)# 
0.30 
(0.11–
0.62)## 
NS NS NS NS NS NS 3.2±0.9$ NS NS NS§ 
NS§§ 
Cont
rol 
3.85 
(1.4) 
NS NS NS 0.20 
(0.06–
0.53)# 
0.41 
(0.17–
0.76)## 
NS NS NS NS NS 4.8±1.3$$ NS NS 
Total 
choleste
rol 
(mg/dL) 
Case 198.3±2
5.5 
201.49±
46.32 
NS 246.65±7.
33 
193±4
2# 
205± 
40## 
242.79±20
.07 
210±23 208±23 240± 
43 
249± 
30.6 
NS 202±37 262±42 185.28±19.
3 
196.78± 
35.28§ 
195.0± 
41.16§§ 
Cont
rol 
189.4±2
5.9 
201.11±
52.49 
NS 247.43±5.
4 
216±3
2# 
208± 
47## 
205±23 202±23 245± 
39 
232± 
22.1 
NS 258±42 196.95± 
35.72 
LDL-C 
(mg/dL) 
Case 112.6±2
1.4 
132.4±3
9.76 
NS 160.19±5.
4 
115±3
1# 
124± 
36## 
166.37± 
18.91 
125±23 121±24 145± 
46 
169± 
32.5 
NS 129±28 208±46 119.66±19.
3 
123.50± 
38.73§ 
120.35± 
42.13§§ 
Cont
rol 
111.8±2
0.9 
132.4±4
5.55 
NS 167.52±6.
95 
129±2
8# 
125± 
37## 
123±25 123±25 148± 
50 
157± 
29.1 
NS 210±40 125.29± 
34.94 
HDL-C 
(mg/dL) 
Case 59.9±19
.6 
38.6±11.
58 
NS 39.76±2.3
2 
53±9# 63±14#
#
 
56.36± 
11.97 
36±4 38±5 65±15 44± 
1.6 
NS 35±8 22±12 46.32 
(46.32–
54.04) 
36.82±5.45§ 
38.78±7.69§§ 
Cont
rol 
60.1±19
.5 
35.51±1
0.42 
NS 43.23±3.0
9 
66±24# 59± 
14## 
37±4 38±5 61±13 43± 
12.0 
NS 24±14 36.38± 
7.67 
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Triglyce
rides 
(mg/dL) 
Case NS 173.46±
117.7 
NS 193.81±1
5.93 
132±9
6# 
101± 
78## 
116.82± 
36.28 
241±42 249±42 146±70 156± 
52.1 
NS 218±226 202±38 61.95±26.5
5 
182.26± 
43.85§ 
176.39± 
27.61§§ 
Cont
rol 
NS 147.79±
80.53 
NS 193.81±1
7.7 
116±7
1# 
106± 
79## 
226±52 237±56 180±66 159± 
52.0 
NS 198±32 170.14± 
47.54 
Glucose 
(mg/dL) 
Case NS NS NS NS 92±12# 163± 
72## 
81.9± 
5.94 
NS NS NS NS NS NS NS NS 161.21± 
19.74§ 
155.04± 
17.94§§ 
Cont
rol 
NS NS NS NS 89±10# 182± 
79## 
NS NS NS NS NS NS 161.19± 
19.97 
SBP 
(mmHg) 
Case NS 148±19 NS 116±3.4 126±1
2# 
128± 
14## 
149± 
6 
117±10 118±10 133±16 142± 
11.8 
NS 107±16 122±14 130±15 127.73± 
11.96§ 
130.43± 
18.59§§ 
Cont
rol 
NS 142±17 NS 122±3.6 123±2
1# 
125±13
##
 
123±10 124±10 134±15 136± 
9.5 
NS 124±12 126.38± 
15.43 
DBP 
(mmHg) 
Case NS 89±7 NS 74±4.3 80±7# 80±9## 97±2 72±5 72±6 76±10 91± 
10.8 
NS NS 78±10 74±8 80.95±7.93§ 
81.82±10.02
§§
 
Cont
rol 
NS 90±9 NS 72±2.5 79±10# 78±9## 74±5 74±5 75±9 86± 
11.0 
NS 76±12 80.71±7.48 
Endothe
lin-1 
(pg/mL) 
Case 3.2±1.7 1.19±1.0
2* 
2.24±0.3
2 
1.46±0.7 0.82±0
.25# 
1.19±0.
42## 
4.5±2.1 1.80±0.6
0 
1.87±0.5
5 
2.03±1.1
8 
1.38±1.56 3.2±1.4 1.7±0.2$ 1.9±1.0 1.28±0.38 1.31±0.33§ 
1.38±0.51§§ 
Cont
rol 
2.98±1.
9 
1.19±0.8
7* 
2.24±0.3
2 
1.48±0.8 0.89±0
.40# 
1.02±0.
29## 
1.84±0.6
0 
1.84±0.5
6 
2.15±0.9
4 
0.57±0.44 3.0±1.2 1.7±0.1$$ NS 1.17±0.33 1.21±0.49 
Values are expressed as mean ± SD or median (25–75 percentiles). ABBREVIATIONS: BMI: body mass index; NS: not stated; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein 
cholesterol; SBP: systolic blood pressure; DBP: diastolic blood pressure; hs-CRP: high-sensitivity C-reactive protein; BMI: body mass index; *the value was provided following 12 week treatment, # denotes at 
risk of type 2 diabetes arm; ## denotes diabetic patients arm; **If total plasma cholesterol was >5.46 mmol/L 8 weeks after randomization or 8 weeks after crossover, the drug dose was doubled to 40 mg/day; $ 
denotes value after statin; $$ denotes value after placebo; § denotes statin group §§ denotes NCB-02 group (two capsules containing curcumin 150 mg twice daily).  
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Supplemental Table 1. Assessment of risk of bias in the included studies using Cochrane criteria. 
Study Ref 
SEQUENCE 
GENERATION 
 
ALLOCATION 
CONCEALMENT 
 
BLINDING OF 
PARTICIPANTS AND 
PERSONNEL 
 
BLINDING OF 
OUTCOME 
ASSESSMENT 
 
INCOMPLETE 
OUTCOME DATA 
 
SELECTIVE 
OUTCOME 
REPORTING 
 
OTHER 
POTENTIAL 
THREATS TO 
VALIDITY 
 
Abou Raya et 
al. 2007 
31
 U U H H L L L 
Asberg et al. 
2003 
32
 L L L L L L H 
Barsuk et al. 
2013 
33
 U U H H L L H 
Dupuis et al. 
1999 
34
 U U L L L L L 
Economides et 
al. 2004 
45
 U L L L L L L 
Glorioso et al. 
1999 
35
 U L L L L L L 
Lee et al. 2002 36 L L L L L L L 
Lee et al. 2005 38 L L L L L L L 
Lee et al. 2009 37 L L L L L L L 
Lewandowski 
et al. 2010 
39
 U U U U L L L 
Li & Hui et al. 
2005 
40
 U U L L U U U 
Mozaffarian et 
al. 2005 
39
 L L L L L L L 
Nakamura et 
al. 2001 
41
 U U U U L L L 
Tehrani et al. 
2013 
43
 U U U U L L L 
Usharani et al. 
2008 
44
 U U H U L L L 
L: low risk of bias; H: high risk of bias; U: unclear risk of bias. 
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FIGURE LEGENDS:  
Figure 1. Flow chart of the number of studies identified and included into the meta-analysis. 
Figure 2. Forest plot detailing weighted mean difference and 95% confidence intervals for the 
impact of statin therapy on plasma endothelin-1 concentrations. Meta-analysis was performed 
using a random-effect model with inverse variance weighting. 
Figure 3. Forest plot detailing weighted mean difference and 95% confidence intervals for the 
impact of statin therapy on plasma endothelin-1 concentrations in trials with treatment durations 
of <12 weeks (above) and > 12 weeks (below). Meta-analysis was performed using a random-
effect model with inverse variance weighting. 
Figure 4. Forest plot detailing weighted mean difference and 95% confidence intervals for the 
impact of statin therapy on plasma endothelin-1 concentrations in trials with statin doses of <40 
mg/day (above) and >40 mg/day (below). Meta-analysis was performed using a random-effect 
model with inverse variance weighting. 
Figure 5. Forest plot detailing weighted mean difference and 95% confidence intervals for the 
impact of statin therapy on plasma endothelin-1 concentrations in trials with hydrophilic 
(above) and hydrophobic (below) statins. Meta-analysis was performed using a random-effect 
model with inverse variance weighting. 
 
Supplemental Figure 1. Leave-one-out sensitivity analysis of the impact of statin therapy on 
plasma endothelin-1 concentrations 
Supplemental Figure 2. Meta-regression plots of the association between mean changes in 
plasma endothelin-1 concentrations and potential moderator variables. The size of each 
circle is inversely proportional to the variance of change. 
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Supplemental Figure 3. Funnel plot detailing publication bias in the studies reporting the 
impact of statin therapy on plasma endothelin-1 concentrations. Open circles represent observed 
published studies; closed circles represent imputed unpublished studies. 
Supplemental Figure 4. Galbraith plot of the weighted mean difference divided by its standard 
error (Z-score) versus the reciprocal standard error (precision) 
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HIGHLIGHTS: 
 
• Raised ET-1 levels may be a risk factor for vascular dysfunction and CVD.   
 
• We showed that statin therapy significantly reduces ET-1 (-0.30 pg/mL).  
 
• Lipophilic, but not a hydrophilic statin had a significant effect on ET-1 reduction 
 
• We need to establish whether lowering ET-1 has a beneficial effect on CV 
events. 
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